[{"indications": "Indications\u00a0type 2 diabetes mellitus not controlled\r\nby metformin alone", "name": "VILDAGLIPTIN WITH METFORMIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs", "VILDAGLIPTIN WITH METFORMIN"], "cautions": "Cautions\u00a0determine renal function before treatment\r\nand at least annually (at least twice a year in patients with additional\r\nrisk factors for renal impairment, or if deterioration suspected); monitor liver function (see below); interactions: Appendix 1 (antidiabetics)Liver toxicity\u00a0Rare reports of liver dysfunction; monitor liver function before treatment and every 3 months for the\r\nfirst year and periodically thereafter; advise patients to seek prompt medical attention if symptoms such\r\nas nausea, vomiting, abdominal pain, fatigue, and dark urine develop; discontinue if jaundice or other signs of liver dysfunction\r\noccurLactic acidosis\u00a0Use with caution\r\nin renal impairment\u2014increased risk of lactic acidosis; avoid if eGFR less than 50\u00a0mL/minute/1.73\u00a0m2. Withdraw or interrupt treatment in those\r\nat risk of tissue hypoxia or sudden deterioration in renal function,\r\nsuch as those with dehydration, severe infection, shock, sepsis, acute\r\nheart failure, respiratory failure or hepatic impairment, or those\r\nwho have recently had a myocardial infarction", "side-effects": "Side-effects\u00a0nausea, vomiting, diarrhoea (usually transient),\r\nabdominal pain, taste disturbance, peripheral oedema, headache, tremor,\r\nanorexia, asthenia, dizziness; less commonly constipation,\r\nhypoglycaemia, arthralgia; rarely hepatic dysfunction\r\n(see also Liver Toxicity above), lactic acidosis (withdraw treatment),\r\ndecreased vitamin-B12 absorption, erythema, pruritus, and\r\nurticaria; very rarely nasopharyngitis, upper respiratory\r\ntract infection; pancreatitis also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201550.htm", "doses": ["See under preparations", "adult over 18 years, 1\r\ntablet twice daily (based on patient\u2019s current metformin dose)", "adult over 18 years, 1\r\ntablet twice daily (based on patient\u2019s current metformin dose)"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies"}, {"indications": "Indications\u00a0type 2 diabetes mellitus (in combination\r\nwith metformin or with a sulfonylurea or with pioglitazone\u2014see also notes above)", "name": "VILDAGLIPTIN", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "6 Endocrine system", "6.1 Drugs used in diabetes", "6.1.2 Antidiabetic drugs", "6.1.2.3 Other antidiabetic drugs", "VILDAGLIPTIN"], "cautions": "Cautions\u00a0monitor liver function (see\r\nbelow); heart failure (avoid if moderate\r\nor severe); interactions: Appendix 1 (antidiabetics)Liver toxicity\u00a0Rare reports of liver dysfunction; monitor liver function before treatment and every 3 months for first\r\nyear and periodically thereafter; advise\r\npatients to seek prompt medical attention if symptoms such as nausea,\r\nvomiting, abdominal pain, fatigue, and dark urine develop; discontinue if jaundice or other signs of liver dysfunction\r\noccur", "side-effects": "Side-effects\u00a0nausea, peripheral oedema, headache, tremor, asthenia,\r\ndizziness; less commonly constipation, hypoglycaemia,\r\narthralgia; rarely hepatic dysfunction (see also\r\nLiver Toxicity above); very rarely nasopharyngitis,\r\nupper respiratory tract infection; pancreatitis also reported", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/201003.htm", "doses": ["adult over 18 years, in\r\ncombination with metformin or pioglitazone, 50\u00a0mg twice daily; in\r\ncombination with a sulfonylurea, 50\u00a0mg daily in the morning"], "pregnancy": "Pregnancy\u00a0avoid\u2014toxicity in animal studies"}]